Favipiravir, also known as T-705, Avigan, or favilavir is a drug designed to treat RNA viral infections DOI and DOI. It is phosphoribosylated by cellular enzymes to its active form, favipiravir-ribofuranosyl-5'-triphosphate (RTP) and inhibits the RNA-dependent RNA polymerase.

Favipiravir has recently been reported to be effective in the treatment of coronavirus patients Link. It appears to be effective in patients showing mild to moderate symptoms, but not effective in patients showing more severe symptoms.

A search of UniChem using the InChiKey gives details of all identifiers and links to clinical studies.

A number of clinical trials have been completed or are ongoing on ClinicalTrials.gov and can be found here.

Whilst it appears to be safe and well tolerated, and it has been approved for flu it has not yet been approved for COVID-19,